Ying Yuan
Second Affiliated Hospital, Zhejiang University, School of Medicine · M.D. Anderson Cancer Center · 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
20
all conditions, ClinicalTrials.gov
NIH grants tied to them
8
18 more share only the name and are not shown
Trial papers
511
PubMed author-name match
Trials
Studies that name Ying Yuan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:11 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07722494 · IBI363 Combined With Bevacizumab for Advanced Colorectal CancerInnovent Biologics (Suzhou) Co. Ltd. · recruiting · Colorectal Cancer · principal investigator
- Ph2NCT07253896 · Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or BevacizumabSecond Affiliated Hospital, Zhejiang University, School of Medicine · recruiting · Safety · principal investigator
- Ph1NCT07247396 · CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal MetastasesSecond Affiliated Hospital, Zhejiang University, School of Medicine · recruiting · Peritoneal Metastases From Colorectal Cancer · principal investigator
- Ph3NCT06992648 · Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · recruiting · Colorectal Cancer Metastatic, Colorectal Cancer Recurrent · principal investigator
- Ph1NCT06972576 · Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph1NCT06946615 · Exploratory Clinical Study of Claudin18.2-Targeted CAR-DC and CAR-T Therapy in Advanced Colorectal CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · recruiting · Colorectal Neoplasia · principal investigator
- N/ANCT06651580 · Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 StudyM.D. Anderson Cancer Center · recruiting · Chronic Pancreatitis, Exocrine Pancreas Carcinoma, Recurrent Acute Pancreatitis · principal investigator
- Ph1NCT06043466 · A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid TumorsChongqing Precision Biotech Co., Ltd · recruiting · Colorectal Cancer, Esophagus Cancer, Gastric Cancer · principal investigator
- Ph2NCT05894837 · Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver MetastasesSecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · Colorectal Cancer, Liver Metastases · study chair
- Ph2NCT05785325 · RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · Colorectal Cancer · study chair
- Ph3NCT05171660 · Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · active not recruiting · Colorectal Cancer Stage IV · principal investigator
- Ph2NCT05160896 · SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · Advanced Metastatic Colorectal Cancer · principal investigator
- Ph2NCT05148143 · RALOX as Second Line Treatment for Advanced Malignant Biliary System TumorSecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · Cholangioadenoma · principal investigator
- Ph1NCT04819516 · Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · Colorectal Cancer · study chair
- Ph2NCT04527068 · QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · Refractory Metastatic Colorectal Cancer, pMMR, MSS · principal investigator
- Ph2NCT04194359 · Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable · study chair
- N/ANCT03672422 · Pediatric Longitudinal Cohort Study of Chronic PancreatitisAliye Uc · completed · Pancreatitis, Chronic, Pancreatitis, Acute · study director
- N/ANCT03058926 · Coordinating and Data Management Center for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic CancerM.D. Anderson Cancer Center · unknown · Chronic Pancreatitis, Diabetes, Pancreatic Cancer · principal investigator
- N/ANCT03046849 · Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Patients Meeting Chinese Lynch Syndrome CriteriaSecond Affiliated Hospital, Zhejiang University, School of Medicine · completed · Lynch Syndrome · principal investigator
- N/ANCT03047226 · Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · completed · Lynch Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 18 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Bioinformatics and Biostatistics CoreP50CA281701 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $243,000 awarded in 2026Same name and institution; not confirmed by an ID
- Biostatistics and Bioinformatics Core (Core C)P50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2026 · $179,850 awarded in 2026Same name and institution; not confirmed by an ID
- Coordinating and Data Management Center for Translational and Basic Science Research in Early LesionsU24CA274212 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 to 2026 · $737,392 awarded in 2026Same name and institution; not confirmed by an ID
- Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC)U01DK108328 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2018 to 2024 · $2,164,185 awarded in 2024Grant number is on one of their registry trials
- Core 2: Biostatistics and Bioinformatics CoreP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2023 · $206,267 awarded in 2023Same name and institution; not confirmed by an ID
- Core 2: Bioinformatics and Biostatistics CoreP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2021 · $163,760 awarded in 2021Same name and institution; not confirmed by an ID
- Biostatistics and Bioinformatics CoreP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2016 to 2020 · $194,115 awarded in 2020Same name and institution; not confirmed by an ID
- Bayesian Adaptive Designs for Oncology Clinical Trials with Late-onset OutcomesR01CA154591 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2011 to 2014 · $286,214 awarded in 2014Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT06651580
- INSPPIRE: Using the natural history of pediatric chronic pancreatitis to identify disease predictors and design therapiesU01DK108334 · NIDDK · UNIVERSITY OF IOWA · PI MARK E. LOWE, Aliye Uc · fiscal years 2015 to 2026Named on NCT03672422
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:11 UTC. The ranking covers the 200 most relevant of 511 PubMed records, and a shared surname and initials can bring in a namesake. All 511 on PubMed
- A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.N Engl J Med · 20203,522 citationsRCR 201.4
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.N Engl J Med · 2022909 citationsRCR 75.5
- Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.N Engl J Med · 2020653 citationsRCR 33.4
- Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.N Engl J Med · 2022580 citationsRCR 37.9
- 384 citationsRCR 22.8
- 379 citationsRCR 11.7
- Effect of Repeated Low-Level Red-Light Therapy for Myopia Control in Children: A Multicenter Randomized Controlled Trial.Ophthalmology · 2022275 citationsRCR 38.7
- Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.J Clin Oncol · 2021259 citationsRCR 13.2
- 238 citationsRCR 17.2
- CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.Nat Med · 2025231 citationsRCR 48.7